Cboe Global Secures 25-Year SPX Rights: Can Volume Boost Growth?

Cboe extended its exclusive SPX options licensing rights through 2051; SPX options volume reached a record 970.6 million contracts in 2025, with average daily volume up 25% year over year to 3.9 million. The longer agreement supports product development and potential transaction-revenue growth, although revised royalties starting in 2027 could raise costs. Cboe shares gained 14.5% over the past year, while consensus estimates project 2026 revenue growth of 15.9% but an earnings decline of 29.2%.

Analysis

The extension removes a long-dated franchise-renewal overhang for Cboe (CBOE), but it does not lock in the economics: revised royalties beginning in 2027 could absorb some incremental transaction revenue. The key underwriting question is therefore net monetization per contract—not headline volume. The article provides no royalty schedule, SPX-specific revenue contribution, or fee yield; verify these before capitalizing record activity into earnings.

Near term, elevated index-options activity supports CBOE, but volume is cyclical and can fade if volatility and hedging demand normalize. Over 1–3 months, watch reported options volume, transaction revenue per contract, and management’s quantified discussion of the 2027 royalty reset. Over 6–18 months, product expansion may deepen the franchise, while CME’s smaller-contract access and Nasdaq’s broad expiration menu offer substitutes for some users. That competition is a constraint on pricing power, not evidence that SPX demand transfers directly to either rival. Tokenized options remain an exploratory possibility, not a base-case catalyst.

The contrarian signal is the disconnect in the supplied estimates: 2026 revenue growth is projected alongside an earnings decline, while the long-duration license is being framed as an uncomplicated growth asset. Until volume converts into earnings after royalties and other costs, the extension merits reduced franchise-risk discounting, not an automatic multiple re-rating.

Key Decisions for Investors

• Maintain a constructive but not aggressive view on CBOE; do not add solely on the license term or record volume. Reassess after the next results using SPX-related transaction revenue, volume, and revenue per contract.
• Set an alert for management disclosure of the 2027 royalty mechanics. A material increase in royalties or weakening revenue per contract would falsify the earnings-conversion thesis even if volumes remain high.
• Treat CME and Nasdaq as competitive watch-list names, not automatic shorts: compare their options-volume growth and product adoption with CBOE’s, while recognizing the products are not interchangeable.
• Avoid pricing tokenized options into estimates until Cboe and S&P DJI disclose a commercial product, regulatory path, and economics.